While advancements in primary breast cancer treatment have achieved remarkable efficacy, one of the paramount challenges remains the mitigation of late relapse. Adjuvant hormone therapies, administered for extended durations spanning five to ten years, serve to suppress tumor regrowth effectively. Nevertheless, up to 30% of ER+ breast cancer patients encounter incurable metastatic recurrence during or after this period, a major contributor to breast cancer mortality in Australia and worldwide. The persistence of malignant cells despite aggressive systemic therapy has perplexed oncologists and researchers, driving the pursuit of novel insights into metastatic dormancy and escape.

Historically, the phenomenon of cancer relapse has been attributed primarily to dormant tumor cells in niches such as bone marrow or other organs, which enter a complete standstill or hibernation state before reawakening. Contrasting this long-standing model, the new findings articulate an alternative yet complementary pathway wherein a subpopulation of breast cancer cells never fully arrests their cell cycle. Instead, they continue to divide at an exceedingly slow pace, maintaining minimal but persistent growth. This mechanism allows micrometastases to gradually develop beneath the radar of standard imaging technologies and biochemical markers.

Associate Professor Liz Caldon, lead investigator and head of the research team at Garvan, elucidates, “While dormant cells represent one form of therapeutic evasion, our work uncovers a covert population of cells that remain metabolically and reproductively active, albeit at a significantly reduced rate. These slow-cycling cells resist hormone therapy not by halting division but by strategically slowing their proliferation to survive and eventually seed metastatic disease.” This paradigm shift in understanding challenges the classical dichotomy of active versus dormant cancer cells and opens new frontiers for therapeutic intervention.

The study meticulously characterized these slow-dividing cells by isolating them over several years using sophisticated cell sorting and growth assays. Contrary to prevailing assumptions linking metastatic potential with rapid proliferation, experimental models demonstrated that slow-cycling cells possess formidable migratory and invasive capabilities. When introduced into animal models, these cells homed efficiently to organs such as bone and lung, establishing micrometastatic colonies. This phenomenon underscores that cellular velocity is not a prerequisite for metastatic competence and reframes the narrative around tumor aggressiveness.

At the molecular level, the team discovered that the Rac1 signaling pathway is instrumental in orchestrating the survival and motility of these slow-growing cells. Rac1, a small GTPase known for its role in cytoskeletal reorganization and cell migration, was found to be upregulated, facilitating the covert expansion and dissemination of micrometastases. Advanced biosensor imaging techniques enabled real-time visualization of Rac1 activation within live cancer cells, providing compelling evidence of its functional relevance in this slow-cycling population.

Crucially, pharmacological inhibition of Rac1 yielded promising therapeutic outcomes. Experimental Rac1 inhibitors effectively curtailed tumor growth and lowered metastatic burden in patient-derived xenograft models, highlighting this pathway as a viable target for future drug development. By interfering with the cellular machinery that sustains slow proliferation and survival, such strategies may thwart metastatic relapse, transforming the clinical landscape for ER+ breast cancer patients.

The implications of these findings ripple profoundly through the realms of oncology and personalized medicine. Current clinical practice relies heavily on standardized hormone therapy regimens, often applied uniformly across patient populations without nuanced molecular stratification. Understanding the biology underpinning slow-cycling cancer cells paves the way for precision approaches that monitor and target these elusive populations. It suggests the potential utility of biomarkers for slow-cycling cells to predict therapeutic resistance and inform treatment duration more accurately.

Associate Professor Caldon emphasizes the translational potential: “Identifying and targeting slow-growing cancer cells provides a new therapeutic lever to prevent metastatic escape. By refining our grasp of their biology, we hope to not only improve surveillance strategies during and post-hormone therapy but also develop adjunct treatments capable of eradicating these hidden reservoirs before they culminate in fatal relapse.”

The quest continues with ongoing investigations spearheaded by the Caldon Lab, which aims to validate Rac1 inhibitors in preclinical and clinical contexts. Evaluating whether these agents can be safely integrated into standard care as prophylactic measures against recurrence constitutes a key priority. Such therapeutic innovation represents a paradigm shift, moving beyond the conventional focus on rapidly dividing tumor cells toward a more comprehensive assault on cancer’s adaptive survival tactics.

Furthermore, the discovery deepens our understanding of tumor heterogeneity—a hallmark of cancer complexity. Tumors comprise diverse cellular subpopulations, each equipped with distinct survival mechanisms. The coexistence of highly proliferative and slow-cycling cells confers adaptability, ensuring tumor persistence under selective pressure from systemic therapies. Targeting these varied subpopulations holistically is essential for durable remission.

This pioneering study underscores the dynamic interplay between cancer cell biology, therapeutic resistance, and clinical outcomes in breast cancer. It encapsulates a leap forward in unravelling the intricate mechanisms governing metastatic dormancy and escape. As the field embraces this nuanced perspective, the prospect of improving patient prognosis through innovative, targeted interventions grows brighter.

In sum, the Garvan team’s revelations cast light on a cryptic facet of cancer biology that has eluded detection for decades. By spotlighting slow-cycling ER+ breast cancer cells as crucial drivers of late relapse, they offer a poignant reminder that cancer’s endurance hinges not only on rapid proliferation but also on strategic stealth. This insight fuels hope for novel therapies that can dismantle the cancer’s silent march and change the trajectory of metastatic breast cancer forever.

Subject of Research: Animals

Article Title: Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

News Publication Date: 11-May-2026

Web References: 10.1038/s41467-026-70683-x

Image Credits: Garvan Institute

Keywords: Breast cancer, Cancer cells, Metastasis, Cancer treatments, Combination therapies, Hormone therapy, Cancer medication, Chemotherapy

ER+ breast cancers owe their growth to signals mediated by estrogen receptors, which hormone therapies aim to block. However, the genetic and epigenetic plasticity of tumors can drive them to evolve mechanisms to bypass these blocks, resulting in relapse and metastatic spread with hormone therapy-resistant disease. Addressing these resistance pathways is crucial as it could dramatically enhance the durability of remission and patient survival. The study led by CSHL Associate Professor Camila dos Santos breaks novel ground by exploring the biological functions of BPTF, a transcription factor previously underestimated in breast cancer biology.

BPTF, or Bromodomain PHD Finger Transcription Factor, regulates chromatin remodeling and gene transcription, thereby influencing cell growth and differentiation. Previous studies had indicated that knocking out BPTF could slow tumor growth but did not prevent tumor formation itself, causing pharmaceutical interest to wane. However, dos Santos’s team revisited BPTF’s role with a nuanced approach. By crossbreeding established murine ER+ breast cancer models with BPTF knockout strains, the researchers uncovered remarkable retention of hormone receptor positivity throughout tumor progression—something unseen before in any mouse model.

What differentiates this model is that the tumors sustained their reliance on estrogen receptor signaling without drifting towards hormone independence, a typical pathway leading to therapy resistance in conventional models. This biological consistency allowed the researchers to test the efficacy of tamoxifen under BPTF-deficient conditions, revealing that tumors exhibited a significant and sustained susceptibility to the drug. This suggests that BPTF activity is instrumental in steering tumors toward resistance phenotypes by potentially altering chromatin states or transcriptional programs associated with hormone receptor regulation.

Further experimental exploration employed advanced organoid cultures, human breast cancer cell lines, and genetically engineered mouse models that recapitulate hormone therapy resistance. Across these sophisticated systems, the abrogation of BPTF synergized with tamoxifen treatment to restore hormone sensitivity, inducing tumor growth arrest. This convergence underscores a potentially targetable axis between epigenetic modulation and hormone therapy response, offering a tangible route to overcoming drug resistance in patients.

The implications of these findings are far-reaching for the clinical management of ER+ breast cancer. Current hormone therapies, although effective initially, provide temporary reprieve for many patients due to the evolution of resistant clones. Targeting BPTF could ‘reprogram’ resistant tumor cells back into a hormone-dependent state, essentially repositioning cancer cells along a vulnerability that current therapies can exploit. Such an approach would not only delay recurrence but could fundamentally change how breast cancers are treated post-resistance development.

This discovery also exemplifies the importance of detailed, mechanistic cancer biology research over simplistic binary analyses of tumor presence or absence. Graduate student Dhivyaa Anandan highlighted that deciphering tumor heterogeneity, growth patterns, and metastatic behaviors was critical to uncovering these insights—affirming that nuanced investigation often reveals therapeutic avenues that remain invisible in more reductive models.

Mechanistically, BPTF’s impact may lie in its chromatin remodeling functions that alter transcriptional landscapes governing estrogen receptor expression and downstream signaling networks. By influencing histone modifications or nucleosome positioning, BPTF may facilitate tumor cell plasticity and adaptive resistance. Disabling BPTF may disrupt these epigenetic programs, restricting tumor cells from rewiring their signaling pathways to evade hormone therapies.

From a translational perspective, pharmacological inhibitors of BPTF or strategies to diminish its expression could be developed as adjuvant treatments alongside tamoxifen and other selective estrogen receptor modulators. This combinatorial approach would potentially enhance patient outcomes by maintaining hormone therapy sensitivity and preventing metastatic dissemination. Given the prevalence of ER+ breast cancer and the substantial subset of patients experiencing recurrence, these findings herald a promising new therapeutic horizon.

Beyond breast cancer, this research spotlights the broad therapeutic potential of targeting transcription factors and chromatin remodelers—oft-overlooked players in oncogenesis that critically modulate cancer cell identity and drug responsiveness. As the research community pioneers novel epigenetic drugs, insights like those from the dos Santos lab provide conceptual and experimental foundations for next-generation cancer therapies.

In conclusion, the discovery that BPTF suppression retains ER+ identity and reinstates hormone therapy sensitivity is a beacon of hope in the fight against breast cancer metastasis and resistance. By integrating sophisticated genetic models, in vitro cultures, and human tumor studies, this research bridges fundamental biology and clinical application, setting the stage for innovative interventions that could transform patient trajectories. The scientific community eagerly anticipates further developments, including clinical translation, toward more durable cures for ER+ breast cancer.

Subject of Research: Estrogen receptor-positive (ER+) breast cancer, hormone therapy resistance, and the role of BPTF transcription factor.

Article Title: Not specified in the source.

News Publication Date: Not specified in the source.

Web References:

• Nature Communications article DOI: 10.1038/s41467-025-64255-8
• Camila dos Santos lab at CSHL: https://www.cshl.edu/research/faculty-staff/camila-dos-santos/

References:

• Original research article in Nature Communications linking BPTF knockout to restored hormone therapy sensitivity in ER+ breast cancer models.

Image Credits: dos Santos lab / Cold Spring Harbor Laboratory

Keywords: Transcription factor binding, Transcription factors, Estrogen, Breast neoplasms, Breast cancer, Metastasis